Sotorasib is more cost-effective in treating patients with KRAS G12C non–small cell lung cancer (NSCLC) compared with ...
VIENNA -- Using sotorasib (Lumakras) as "lead-in" therapy prior to combining it with immunotherapy was feasible as first-line therapy for patients with advanced KRAS G12C non-small cell lung cancer ...
Treating severe KRAS G12C-related arteriovenous malformations with sotorasib (Lumakras) appeared to be effective in a small French study. Two adult patients with the life-threatening condition who ...
French investigators are warning clinicians who treat patients with non–small cell lung cancer (NSCLC) not to initiate treatment with sotorasib within 30 days of an immunotherapy infusion with an anti ...
Sotorasib conferred durable clinical benefit among previously treated patients with KRAS p.G12C-mutated non-small cell lung cancer, according to results of the phase 2 CodeBreaK 100 trial presented ...
The KRAS mutation occurs in 13% of non–small cell lung cancers (NSCLC) and leads to worse outcomes in NSCLC. The findings about the oral agent were published simultaneously in the New England Journal ...
KRAS G12C is a mutation that occurs in approximately 3 to 4% of patients with metastatic colorectal cancer. Monotherapy with KRAS G12C inhibitors has yielded only modest efficacy. Combining the KRAS ...
Participants with advance non-small cell lung cancer and colorectal cancer experienced the greatest benefits in this first-in-human phase 1 clinical trial. DUARTE, Calif.--(BUSINESS WIRE)--A phase 1 ...
A phase 1 clinical trial of sotorasib (AMG 510) in patients with heavily pretreated advanced solid tumors shows encouraging anti-cancer activity, especially in lung and colorectal cancers, reports a ...
1.1 Sotorasib is recommended for use within the Cancer Drugs Fund as an option for treating KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose ...
The appraisal committee considered evidence submitted by Amgen, a review of this submission by the evidence review group (ERG), and responses from stakeholders. See the committee papers for full ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback